Novo Nordisk ASMEX:NOVOBN +3.85%79 EBITDA Margin % is 71.48% as of Mar. 2026, which is 54% above its 10-year median of 46.48. GuruFocus rates MEX:NOVOBN with a GF Score™ of 79/100 and a GF Value™ of MXN2,387.36 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 955 Drug Manufacturers companies, Novo Nordisk AS ranks better than 97.28% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Novo Nordisk AS's EBITDA for the
three
months ended in Mar. 2026 was MXN193,029 Mil. Novo Nordisk AS's Revenue for the
three
months ended in Mar. 2026 was MXN270,054 Mil. Therefore, Novo Nordisk AS's EBITDA margin for the quarter that ended in Mar. 2026 was 71.48%.
Novo Nordisk AS (MEX:NOVOBN) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Novo Nordisk AS EBITDA Margin % Related Terms
Novo Nordisk AS EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Novo Nordisk AS's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:NOVOBN vs LLY, JNJ, ABBV: EBITDA Margin % Comparison
For the Drug Manufacturers - General subindustry, Novo Nordisk AS's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novo Nordisk AS EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Novo Nordisk AS's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Novo Nordisk AS's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novo Nordisk AS (MEX:NOVOBN) has a EBITDA Margin % of 71.48% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Novo Nordisk AS and its competitors. This is 54% above median its historical median of 46.48. Over the past decade, Novo Nordisk AS's EBITDA Margin % has ranged from 43.40 to 55.38. According to the industry distribution chart, Novo Nordisk AS ranks #26 out of 955 companies in the Drug Manufacturers industry, placing it in the top 2.7%.
Is Novo Nordisk AS's EBITDA Margin % too high?
Novo Nordisk AS's current EBITDA Margin % of 71.48% is 54% above median its 10-year median of 46.48. Over the past 10 years, this metric has ranged from a low of 43.40 to a high of 55.38. The Drug Manufacturers industry median EBITDA Margin % is 12.39. Novo Nordisk AS's value of 71.48% is 476.9% above this industry median. Based on the distribution chart, Novo Nordisk AS ranks #26 out of 955 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Novo Nordisk AS has a GF Score™ of 79/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Novo Nordisk AS's EBITDA Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Novo Nordisk AS ranks #26 out of 955 companies for EBITDA Margin %. This places Novo Nordisk AS in the top 3% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.39. Novo Nordisk AS's value of 71.48% is 476.9% above this benchmark. Historically, Novo Nordisk AS's own EBITDA Margin % has ranged from 43.40 to 55.38 over the past decade. While the company's 10-year median is 46.48 vs. the industry median of 12.39, Novo Nordisk AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.39, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Novo Nordisk AS's current EBITDA Margin % of 71.48% is 476.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Novo Nordisk AS and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novo Nordisk AS's current EBITDA Margin % is 71.48%, which is 54% above median its own 10-year median of 46.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novo Nordisk AS stock overvalued right now?
Based on GuruFocus' analysis, Novo Nordisk AS (MEX:NOVOBN) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN2,387.36, compared to a current price of MXN810.00 — trading 66.1% below its estimated fair value. The current EBITDA Margin % is 71.48%, which is 54% above median its 10-year median of 46.48 and 476.9% above the Drug Manufacturers industry median of 12.39. Novo Nordisk AS's overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Novo Nordisk AS (MEX:NOVOBN), the current EBITDA Margin % is 71.48% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novo Nordisk AS (MEX:NOVOBN) Overvalued in 2026?
Based on GuruFocus' analysis, Novo Nordisk AS stock appears to be undervalued.
The current stock price of MXN810.00 is trading 66.1% below its estimated GF Value™ of MXN2,387.36.
GuruFocus considers Novo Nordisk AS to be Significantly Undervalued.
Key valuation signals for MEX:NOVOBN:
EBITDA Margin %: 71.48% (54% above median its 10-year median of 46.48)
GF Value™: MXN2,387.36 vs. price of MXN810.00 (66.1% below fair value)
Industry Position: 476.9% above the Drug Manufacturers median (#26 of 955)
No single metric tells the full story. See the MEX:NOVOBN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
79GF Score
Get the complete analysis for MEX:NOVOBN
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:NOVOBN has been successfully added to your 
